Drug Profile
Teriparatide biosimilar - Suzhou Genemen Biotech
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Suzhou Genemen Biotech
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Male osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Male-osteoporosis in China (SC, Injection)
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Postmenopausal-osteoporosis in China (SC, Injection)
- 26 Nov 2015 Clinical trials in Male osteoporosis in China (SC)